Cancer Care Goes Virtual in Response to COVID-19.

Abstract:

:Amid concerns over the spread of COVID-19, oncology practices have "gone virtual," with video appointments scheduled for any service that does not require diagnostic testing or treatment.

journal_name

Cancer Discov

journal_title

Cancer discovery

authors

doi

10.1158/2159-8290.CD-NB2020-027

subject

Has Abstract

pub_date

2020-06-01 00:00:00

pages

755

issue

6

eissn

2159-8274

issn

2159-8290

pii

2159-8290.CD-NB2020-027

journal_volume

10

pub_type

杂志文章
  • Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset.

    abstract:UNLABELLED:Identifying genetic alterations that prime a cancer cell to respond to a particular therapeutic agent can facilitate the development of precision cancer medicines. Cancer cell-line (CCL) profiling of small-molecule sensitivity has emerged as an unbiased method to assess the relationships between genetic or c...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-15-0235

    authors: Seashore-Ludlow B,Rees MG,Cheah JH,Cokol M,Price EV,Coletti ME,Jones V,Bodycombe NE,Soule CK,Gould J,Alexander B,Li A,Montgomery P,Wawer MJ,Kuru N,Kotz JD,Hon CS,Munoz B,Liefeld T,Dančík V,Bittker JA,Palmer M,

    更新日期:2015-11-01 00:00:00

  • Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based ubiquitination assay.

    abstract::E3 ubiquitin ligases are of interest as drug targets for their ability to regulate protein stability and function. The oncogene Mdm2 is an attractive E3 ligase to target, as it is the key negative regulator of the tumor suppressor p53, which controls the transcription of genes involved in cell fate. Overexpression of ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-11-0104

    authors: Herman AG,Hayano M,Poyurovsky MV,Shimada K,Skouta R,Prives C,Stockwell BR

    更新日期:2011-09-01 00:00:00

  • IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma.

    abstract::Pancreatic ductal adenocarcinoma (PDAC) is poorly responsive to therapies and histologically contains a paucity of neoplastic cells embedded within a dense desmoplastic stroma. Within the stroma, cancer-associated fibroblasts (CAF) secrete tropic factors and extracellular matrix components, and have been implicated in...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-18-0710

    authors: Biffi G,Oni TE,Spielman B,Hao Y,Elyada E,Park Y,Preall J,Tuveson DA

    更新日期:2019-02-01 00:00:00

  • BRAF Dimerization: An Underlying Resistance Mechanism in Low-Grade Pediatric Gliomas.

    abstract:: BRAF fusions and mutations are the most frequent genetic alterations in pediatric low-grade gliomas. The work from Wang and colleagues identifies an acquired secondary BRAF mutation that confers resistance to pharmacologic BRAF inhibition in a BRAFV600E glioma. The authors demonstrate that the mu...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-18-0784

    authors: Romano G,Kwong LN

    更新日期:2018-09-01 00:00:00

  • USP2a activation of MYC in prostate cancer.

    abstract::Ubiquitin-specific protease 2a, a deubiquitinating enzyme, elevates MYC levels in prostate cancer cells via its stabilization of MDM2, undermining p53 regulation of microRNAs that target MYC mRNA. ...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-12-0027

    authors: Nelson WG,De Marzo AM,Yegnasubramanian S

    更新日期:2012-03-01 00:00:00

  • CD30-Targeted CAR T Cells Show Promise in Pretreated Hodgkin Lymphoma.

    abstract::CD30-directed CAR T cells were safe and produced a 62% overall response rate in Hodgkin lymphoma. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-RW2020-111

    authors:

    更新日期:2020-09-01 00:00:00

  • Serine biosynthesis is a metabolic vulnerability in FLT3-ITD-driven acute myeloid leukaemia.

    abstract::Internal tandem duplication of the FMS-like tyrosine kinase 3 gene (FLT3-ITD) occurs in 30% of poor prognosis acute myeloid leukaemias (AMLs). Limited clinical efficacy of FLT3 inhibitors highlights the need for alternative therapeutic modalities in this subset of disease. Using human and murine models of FLT3-ITD-dri...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-20-0738

    authors: Bjelosevic S,Gruber E,Newbold A,Shembrey C,Devlin JR,Hogg SJ,Kats L,Todorovski I,Fan Z,Abrehart TC,Pomilio G,Wei A,Gregory GP,Vervoort SJ,Brown KK,Johnstone RW

    更新日期:2021-01-12 00:00:00

  • First Comprehensive Companion Diagnostic OK'd.

    abstract::The FDA has approved F1CDx, a comprehensive companion diagnostic test that can detect genetic alterations and two genomic signatures in any type of solid tumor. Patients with five common types of advanced cancer can be matched to one of 17 targeted therapies with this single test. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2017-182

    authors:

    更新日期:2018-03-01 00:00:00

  • Blocking IDO1 Helps Shrink Bladder, Cervical Tumors.

    abstract::Findings from a phase I/IIa study indicate that combining the investigational indoleamine 2,3-dioxygenase 1 inhibitor BMS-986205 with nivolumab is safe and boosts response rates among patients with bladder and cervical cancers. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2017-167

    authors:

    更新日期:2018-01-01 00:00:00

  • Cancer cell metabolism: one hallmark, many faces.

    abstract::Cancer cells must rewire cellular metabolism to satisfy the demands of growth and proliferation. Although many of the metabolic alterations are largely similar to those in normal proliferating cells, they are aberrantly driven in cancer by a combination of genetic lesions and nongenetic factors such as the tumor micro...

    journal_title:Cancer discovery

    pub_type: 杂志文章,评审

    doi:10.1158/2159-8290.CD-12-0345

    authors: Cantor JR,Sabatini DM

    更新日期:2012-10-01 00:00:00

  • Privacy protection in whole-genome sequencing.

    abstract::A report from the Presidential Commission for the Study of Bioethical Issues offers several recommendations to help protect the privacy of patients who have whole-genome sequencing. ...

    journal_title:Cancer discovery

    pub_type: 新闻

    doi:10.1158/2159-8290.CD-NB2012-124

    authors:

    更新日期:2012-12-01 00:00:00

  • Unfurling the Genetic Map of Sarcomas.

    abstract::An international team of researchers has uncovered multiple new germline mutations that may influence the development of sarcomas. Notably, they found that variants in several DNA damage sensing and repair genes contribute greatly to sarcoma risk, including BRCA2, ATM, ATR, and ERCC2. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2016-108

    authors:

    更新日期:2016-10-01 00:00:00

  • Genomic Screens Identify Genes That Regulate MHC-I Expression in DLBCL.

    abstract::MHC-I and MHC-II regulators in lymphomas, some of which had subtype or tumor specificity, were identified. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-RW2020-178

    authors:

    更新日期:2020-12-11 00:00:00

  • Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers.

    abstract::We performed cytosine methylation sequencing on genetically diverse patients with acute myeloid leukemia (AML) and found leukemic DNA methylation patterning is primarily driven by nonpromoter regulatory elements and CpG shores. Enhancers displayed stronger differential methylation than promoters, consisting predominan...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-16-1032

    authors: Glass JL,Hassane D,Wouters BJ,Kunimoto H,Avellino R,Garrett-Bakelman FE,Guryanova OA,Bowman R,Redlich S,Intlekofer AM,Meydan C,Qin T,Fall M,Alonso A,Guzman ML,Valk PJM,Thompson CB,Levine R,Elemento O,Delwel R,Meln

    更新日期:2017-08-01 00:00:00

  • Improved survival ends nivolumab trial early.

    abstract::A phase III trial testing nivolumab to treat advanced melanoma was stopped early due to improved overall survival compared with standard chemotherapy. ...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-NB2014-104

    authors:

    更新日期:2014-09-01 00:00:00

  • New FDA Center May Speed Approval Process.

    abstract::The FDA's new Oncology Center of Excellence is aimed at consolidating the approval processes for new cancer drugs, biologics, and devices. Richard Pazdur, MD, current director of the agency's Office of Hematology and Oncology Products within the Center for Drug Evaluation and Research will serve as the new center's ac...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2016-092

    authors:

    更新日期:2016-09-01 00:00:00

  • Naïve T-cell Deficits at Diagnosis and after Chemotherapy Impair Cell Therapy Potential in Pediatric Cancers.

    abstract::Translational data on chimeric antigen receptor (CAR) T-cell trials indicate that the presence of naïve T cells in the premanufacture product is important to clinical response and persistence. In anticipation of developing CAR trials for other tumors, we investigated the T-cell distribution from children with solid tu...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-18-1314

    authors: Das RK,Vernau L,Grupp SA,Barrett DM

    更新日期:2019-04-01 00:00:00

  • E-cigarettes Best Other Cessation Tools.

    abstract::Electronic cigarettes (e-cigarettes) may be an effective tool for smoking cessation. In a randomized trial, researchers found that 18% of those assigned to use e-cigarettes were smoke-free after a year, compared with 9.9% of those assigned to nicotine replacement therapies such as patches and gum. However, those in th...

    journal_title:Cancer discovery

    pub_type: 评论,新闻

    doi:10.1158/2159-8290.CD-NB2019-018

    authors:

    更新日期:2019-04-01 00:00:00

  • Measuring oncogenic signaling pathways in cancer with PET: an emerging paradigm from studies in castration-resistant prostate cancer.

    abstract:UNLABELLED:As parallel advances in cancer biology and drug development continue to elevate the role of targeted therapies in oncology, the need for imaging biomarkers that systematically measure the biology associated with therapeutic intervention has become more urgent. Although the molecular imaging community has a c...

    journal_title:Cancer discovery

    pub_type: 杂志文章,评审

    doi:10.1158/2159-8290.CD-12-0178

    authors: Evans MJ

    更新日期:2012-11-01 00:00:00

  • Shades of T790M: Intratumor Heterogeneity in EGFR-Mutant Lung Cancer.

    abstract::In the setting of recent exciting clinical results and numerous ongoing trials, Piotrowska and colleagues explore mechanisms of acquired resistance to the mutant-specific EGFR inhibitor rociletinib, and demonstrate that loss of T790M, EGFR amplification, and small-cell transformation are all clinically relevant mechan...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-15-0616

    authors: Ichihara E,Lovly CM

    更新日期:2015-07-01 00:00:00

  • A combined epigenetic therapy equals the efficacy of conventional chemotherapy in refractory advanced non-small cell lung cancer.

    abstract::A new study by Juergens and colleagues provides the first successful example of a combined epigenetic therapy capable of achieving results similar to those of conventional chemotherapy in refractory metastatic non-small cell lung cancer. Furthermore, the authors describe interesting blood-based DNA methylation biomark...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-11-0271

    authors: Rodríguez-Paredes M,Esteller M

    更新日期:2011-12-01 00:00:00

  • Upping Enrollment of Veterans in Trials.

    abstract::The NCI and Department of Veterans Affairs (VA) are collaborating on the NCI and VA Interagency Group to Accelerate Trials Enrollment, or NAVIGATE, which will launch at 12 VA facilities across the country. The program aims to increase participation of veterans with cancer in NCI-sponsored clinical trials. ...

    journal_title:Cancer discovery

    pub_type: 新闻

    doi:10.1158/2159-8290.CD-NB2018-097

    authors:

    更新日期:2018-08-01 00:00:00

  • Tetanus shot may improve glioblastoma treatment.

    abstract::Preconditioning the immune system with a tetanus/diphtheria toxoid significantly improved the effectiveness of dendritic cell immunotherapy and extended overall survival in a small, randomized study of patients with glioblastoma. ...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-NB2015-053

    authors:

    更新日期:2015-06-01 00:00:00

  • From breaking bad to worse: exploiting homologous DNA repair deficiency in cancer.

    abstract::DNA repair deficiencies are common among cancer cells and represent a potential vulnerability that might be exploited by targeting compensatory repair pathways. However, the identification of synthetically lethal combinations of DNA repair defects, although of significant clinical relevance, has been somewhat anecdota...

    journal_title:Cancer discovery

    pub_type:

    doi:10.1158/2159-8290.CD-14-0316

    authors: Hemann MT

    更新日期:2014-05-01 00:00:00

  • Intraductal Transplantation Models of Human Pancreatic Ductal Adenocarcinoma Reveal Progressive Transition of Molecular Subtypes.

    abstract::Pancreatic ductal adenocarcinoma (PDAC) is the most lethal common malignancy, with little improvement in patient outcomes over the past decades. Recently, subtypes of pancreatic cancer with different prognoses have been elaborated; however, the inability to model these subtypes has precluded mechanistic investigation ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-20-0133

    authors: Miyabayashi K,Baker LA,Deschênes A,Traub B,Caligiuri G,Plenker D,Alagesan B,Belleau P,Li S,Kendall J,Jang GH,Kawaguchi RK,Somerville TDD,Tiriac H,Hwang CI,Burkhart RA,Roberts NJ,Wood LD,Hruban RH,Gillis J,Krasnitz

    更新日期:2020-10-01 00:00:00

  • Fasting May Complement Endocrine Therapy.

    abstract::Preliminary findings from a recent study suggest that combining intermittent fasting or a fasting-mimicking diet with endocrine therapy for hormone receptor-positive breast cancer may improve treatment efficacy and reduce side effects. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2020-084

    authors:

    更新日期:2020-11-01 00:00:00

  • Tweaking Transcription to Stop AML Cell Growth.

    abstract::A new compound with anti-leukemia activity perturbs gene transcription by modulating super-enhancer activity. ...

    journal_title:Cancer discovery

    pub_type: 新闻

    doi:10.1158/2159-8290.CD-NB2015-149

    authors:

    更新日期:2015-12-01 00:00:00

  • NCI Paylines Drop as Grant Applications Climb.

    abstract::The overall budget for the NCI has increased by about $1 billion since 2009, yet the payline for new R01 grants has continued to decrease, largely due to an influx of R01 grant applications. Researchers, troubled by this trend, are wondering why the NCI is receiving so many more applications and what can be done to im...

    journal_title:Cancer discovery

    pub_type: 新闻

    doi:10.1158/2159-8290.CD-NB2019-041

    authors:

    更新日期:2019-05-01 00:00:00

  • The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells.

    abstract::To study mechanisms underlying resistance to the BCL2 inhibitor venetoclax in acute myeloid leukemia (AML), we used a genome-wide CRISPR/Cas9 screen to identify gene knockouts resulting in drug resistance. We validated TP53, BAX, and PMAIP1 as genes whose inactivation results in venetoclax resistance in AML cell lines...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-19-0125

    authors: Nechiporuk T,Kurtz SE,Nikolova O,Liu T,Jones CL,D'Alessandro A,Culp-Hill R,d'Almeida A,Joshi SK,Rosenberg M,Tognon CE,Danilov AV,Druker BJ,Chang BH,McWeeney SK,Tyner JW

    更新日期:2019-07-01 00:00:00

  • Direct-to-Consumer Test for BRCA Mutations Authorized.

    abstract::The FDA authorized 23andMe to market the first direct-to-consumer test to check for three BRCA1/2 mutations associated with a higher risk of developing breast, ovarian, and prostate cancers. The mutations are most commonly found in about 2% of women of Ashkenazi Jewish descent. ...

    journal_title:Cancer discovery

    pub_type: 新闻

    doi:10.1158/2159-8290.CD-NB2018-031

    authors:

    更新日期:2018-05-01 00:00:00